Vortioxetine hydrobromide is under clinical development by H. Lundbeck and currently in Phase II for Bipolar Disorder (Manic Depression). According to GlobalData, Phase II drugs for Bipolar Disorder ...
mhri.org Objective: To study the efficacy and safety of galantamine hydrobromide ER for the enhancement of cognition in non-demented Parkinson’s patients (PD). Methods: Sixty-nine non-demented PD ...
mhri.org Objective: To study the efficacy and safety of galantamine hydrobromide ER for the enhancement of cognition in non-demented Parkinson’s patients (PD). Methods: Sixty-nine non-demented PD ...